EU Post Market Clinical Follow-Up Study of the Venclose System for Saphenous Vein Incompetence

Venclose, Inc.1 site in 1 country25 target enrollmentMay 11, 2020

ConditionsChronic Venous Insufficiency

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Chronic Venous Insufficiency
Sponsor: Venclose, Inc.
Enrollment: 25
Locations: 1
Primary Endpoint: Vein Occlusion Rate
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a prospective, non-randomized study in which patients who meet eligibility criteria and consent to participate will undergo a minimally invasive procedure using radiofrequency (RF) energy for ablation of the great saphenous vein (GSV).

Detailed Description

Subjects who meet eligibility criteria will undergo a procedure using the Venclose Radiofrequency (RF) System to treat the great saphenous vein. The technique involves percutaneous access and insertion of the endovenous sectional radiofrequency (EVSRF™) catheter into the target vein under ultrasound guidance and relies on the use of local anesthesia and thermal energy, from a radiofrequency generator, applied to the target vein. After each treatment, the EVSRF™ catheter is withdrawn a single length of the heating coil and another treatment is performed, until the entire vessel has been treated. After the treatment procedure, subjects will be evaluated four (4) times to assess vein recanalization and reflux, and to determine the incidence of adverse events.

Registry

clinicaltrials.gov

Start Date

May 11, 2020

End Date

August 2, 2021

Last Updated

4 years ago

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Venclose, Inc.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subject is male or female and 18 to 80 years old (inclusive) at time of enrollment (signing of consent).
•Subject has significant venous reflux by Duplex Ultrasound (DUS), defined as reverse flow with reflux duration greater than 0.5 seconds after the Valsalva maneuver or distal augmentation while the patient is standing or in reverse Trendelenburg position.
•Subject is eligible for endovascular treatment, as determined by the treating investigator.
•Subject's general physical condition allows for a significant amount of ambulation after the procedure, as determined by the treating investigator.
•Subject is willing and able to complete study requirements, including all follow-up visits and assessments.
•Subject voluntarily provides written informed consent to participate in this study.

Exclusion Criteria

•There is evidence of old or fresh thrombus in the subject's diseased vein segment to be treated, as determined by Duplex Ultrasound (DUS) within 2 weeks prior to the index procedure.
•In the judgment of the treating investigator heat energy delivery to the subject would be contraindicated.
•Subject is concurrently participating in another interventional clinical trial.
•Subject is pregnant or plans to be pregnant or lactating at the time of the treatment procedure.
•Subject has known or suspected allergies or contraindications to any general or local anesthetic agents and/or any antibiotic medication that cannot be adequately pre-treated.